Achievement of response over time with fremanezumab in the treatment of chronic and episodic migraine (vol 19, pg P11, 2018)

被引：0
|
作者：
Silberstein, Stephen D. [1 ]
Lipton, Richard B. [2 ]
Diamond, Merle L. [3 ]
Cohen, Joshua M. [4 ]
Yang, Ronghua [4 ]
Jiang, Bo [4 ]
机构：
[1] Thomas Jefferson Univ, Jefferson Headache Ctr, Philadelphia, PA 19107 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Diamond Headache Clin Ltd, Chicago, IL USA
[4] Teva Pharmaceut, Frazer, PA USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 39 条
  • [31] p11 in Cholinergic Interneurons of the Nucleus Accumbens Is Essential for Dopamine Responses to Rewarding Stimuli (vol 5, pg e0332-18.2018, 2018)
    Hanada, Y.
    Kawahara, Y.
    Ohnishi, Y. N.
    Shuto, T.
    Kuroiwa, M.
    Sotogaku, N.
    Greengard, P.
    Sagi, Y.
    Nishi, A.
    ENEURO, 2018, 5 (06)
  • [32] The observation on different effectiveness between the embedding needle therapy and medication in the preventative treatment of chronic migraine (vol 28, pg 242, 2018)
    Zhao, Zheng
    WORLD JOURNAL OF ACUPUNCTURE-MOXIBUSTION, 2021, 31 (03) : 248 - 248
  • [33] Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study
    Spierings, Egilius L. H.
    Ning, Xiaoping
    Campos, Verena Ramirez
    Cohen, Joshua M.
    Barash, Steve
    Buse, Dawn C.
    HEADACHE, 2021, 61 (09): : 1376 - 1386
  • [34] The impact of offering monthly and quarterly dosing options for a new class of migraine preventive therapy on likelihood of acceptance and adherence in adults with migraine (vol 19, pg P137, 2018)
    Cowan, Robert
    Cohen, Joshua
    Rosenman, Erik
    Fitzgerald, Tim
    Iyer, Ravi
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [35] Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia (vol 24, pg 563, 2018)
    Fraietta, Joseph A.
    Lacey, Simon F.
    Orlando, Elena J.
    Pruteanu-Malinici, Iulian
    Gohil, Mercy
    Lundh, Stefan
    Boesteanu, Alina C.
    Wang, Yan
    O'Connor, Roddy S.
    Hwang, Wei-Ting
    Pequignot, Edward
    Ambrose, David E.
    Zhang, Changfeng
    Wilcox, Nicholas
    Bedoya, Felipe
    Dorfmeier, Corin
    Chen, Fang
    Tian, Lifeng
    Parakandi, Harit
    Gupta, Minnal
    Young, Regina M.
    Johnson, F. Brad
    Kulikovskaya, Irina
    Liu, Li
    Xu, Jun
    Kassim, Sadik H.
    Davis, Megan M.
    Levine, Bruce L.
    Frey, Noelle V.
    Siegel, Donald L.
    Huang, Alexander C.
    Wherry, E. John
    Bitter, Hans
    Brogdon, Jennifer L.
    Porter, David L.
    June, Carl H.
    Melenhorst, J. Joseph
    NATURE MEDICINE, 2021, 27 (03) : 561 - 561
  • [36] Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma (vol 19, pg 387, 2018)
    Taus, Alvaro
    Camacho, Laura
    Rocha, Pedro
    Hardy-Werbin, Max
    Pijuan, Lara
    Piquer, Gabriel
    Lopez, Eva
    Dalmases, Alba
    Longaron, Raquel
    Clave, Sergi
    Salido, Marta
    Albanell, Joan
    Bellosillo, Beatriz
    Arriola, Edurne
    CLINICAL LUNG CANCER, 2020, 21 (04) : E233 - E233
  • [37] 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies (vol 58, pg 1347, 2018)
    Rosen, N.
    Pearlman, E.
    Ruff, D.
    Nagy, Jim A.
    HEADACHE, 2019, 59 (08): : 1428 - 1428
  • [38] Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: Differences between women and men in relation to the ace gene polymorphism (vol 11, pg 88, 2000)
    Ruggenenti, P
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2000, 11 (05): : U67 - U67
  • [39] Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. (vol 111, pg 1039, 2008)
    Gambacorti-Passerini, Carlo
    BLOOD, 2008, 112 (02) : 452 - 452
1234